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Background: Multiple sclerosis (MS) is an autoimmune inflammatory disease of the central nervous system (CNS).
In recent years, it has been found that cells such as human amnion epithelial cells (hAECs) have the ability to
modulate immune responses in vitro and in vivo and can differentiate into multiple cell lineages. Accordingly, we
investigated the immunoregulatory effects of hAECs as a potential therapy in an MS-like disease, EAE (experimental
autoimmune encephalomyelitis), in mice.
Methods: Using flow cytometry, the phenotypic profile of hAECs from different donors was assessed. The
immunomodulatory properties of hAECs were examined in vitro using antigen-specific and one-way mixed
lymphocyte proliferation assays. The therapeutic efficacy of hAECs was examined using a relapsing-remitting
model of EAE in NOD/Lt mice. T cell responsiveness, cytokine secretion, T regulatory, and T helper cell phenotype
were determined in the peripheral lymphoid organs and CNS of these animals.
Results: In vitro, hAECs suppressed both specific and non-specific T cell proliferation, decreased pro-inflammatory
cytokine production, and inhibited the activation of stimulated T cells. Furthermore, T cells retained their naïve
phenotype when co-cultured with hAECs. In vivo studies revealed that hAECs not only suppressed the development of
EAE but also prevented disease relapse in these mice. T cell responses and production of the pro-inflammatory cytokine
interleukin (IL)-17A were reduced in hAEC-treated mice, and this was coupled with a significant increase in the number
of peripheral T regulatory cells and naïve CD4+ T cells. Furthermore, increased proportions of Th2 cells in the peripheral
lymphoid organs and within the CNS were observed.
Conclusion: The therapeutic effect of hAECs is in part mediated by inducing an anti-inflammatory response within the
CNS, demonstrating that hAECs hold promise for the treatment of autoimmune diseases like MS.
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Multiple sclerosis (MS) is an inflammatory disease of the
central nervous system (CNS) [1]. Current knowledge sug-
gests that the disease is maintained by auto-reactive T cells
that target proteins expressed predominantly in myelin
and, to a lesser extent on axons, which ultimately results in
CNS tissue injury [2]. A number of therapeutic approaches
using immunomodulatory or immunosuppressive drugs* Correspondence: natalie.payne@monash.edu; claude.bernard@monash.edu
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creativecommons.org/publicdomain/zero/1.0/such as interferon-β, glatiramer acetate, natalizumab, and
Fingolimod (FTY720) have been designed to target the im-
mune component of the disease process [3]. While these
treatments are beneficial in halting the disease in approxi-
mately 30 % of relapsing-remitting (RR)-MS patients, they
are only partially effective and have little impact on disease
progression [4]. For this reason, there is a desperate need
for alternative therapies to improve the outcomes for the
majority of MS patients. Improved therapeutic outcomes
will require the suppression of the inflammatory response,
restoration of immunological tolerance, and the incorpor-
ation of neuroprotective strategies. For these reasons, stemss article distributed under the terms of the Creative Commons Attribution
by/4.0), which permits unrestricted use, distribution, and reproduction in any
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a potential treatment for MS.
One proposed stem cell source is human amnion epi-
thelial cells (hAECs). These cells are isolated from the
epithelial layer of the amniotic membrane, the innermost
layer of the fetal membranes that surround the fetus [5].
The amnion is originally derived from embryonic ectoderm
[6, 7] with differentiation of hAECs from the epiblast oc-
curring around day 8 of human pregnancy, before gastrula-
tion, at a time when the cells are still pluripotent. As a
result of this early divergence, hAECs retain a high level of
pluripotency as evidenced by the expression of several em-
bryonic stem cell (ESC) markers including OCT-4, nanog,
SSEA-3, SSEA-4, TRA 1-60, and c-kit [8–11]. hAECs
are claimed to be immune privileged in so far as they do
not express human leukocyte antigen (HLA) class II or
co-stimulatory molecules [12, 13], theoretically making
them potential candidates in allogeneic settings. Given
that, on average, about 100–200 million hAECs can be
isolated from a term placenta [13], these cells present
an abundant source of potential regenerative tissue. More-
over, their collection does not hold ethical constraints in
comparison with other stem cell sources such as ESCs. In
vitro studies have shown that hAECs can generate clinic-
ally relevant cell types from ectoderm, mesoderm, and
endoderm, such as cardiomyocytes, myocytes, osteocytes,
adipocytes, pancreatic cells, hepatocytes, as well as neural
and astrocytic cells [9, 10, 14]. More poignantly, investiga-
tions into their immunomodulatory properties have
shown that hAECs inhibit cells of the innate and adaptive
immune system, as shown by the inhibition of neutrophil
and macrophage migration by secrete factors [8, 15] and
reduction of both T and B cell proliferation [5, 16] in vitro.
The potential of hAECs for the treatment of MS has
recently been highlighted by transplantation studies in
experimental autoimmune encephalomyelitis (EAE) by us
and others [17, 18], which links the amelioration of EAE
with the capacity of hAECs to suppress inflammation.
However, the mechanisms behind the suppression of dis-
ease are not well understood. It has also been claimed that
hAECs are capable of homing to sites of inflammation
[19], including the brain [20]. It is noteworthy that amnion
has been used clinically for over 30 years for the treatment
of dural defects [21], burns [22, 23], ocular surface disease
[24], and other numerous eye diseases [25–27], thus estab-
lishing their strong safety profile. The current study ex-
tends on previous findings by showing that hAECs can
significantly suppress in vitro T cell activation, prolifer-
ation, and cytokine production. When administered at the
time of disease onset in a RR-EAE model, hAEC trans-
plantation significantly attenuated disease through increas-
ing the number of T regulatory cells, increasing the
pool of peripheral naïve CD4+ T cells, and promoting a
shift towards a Th2 dominant environment. This studydemonstrates that hAECs are highly immunomodula-
tory and may have potential as a therapy for MS.
Materials and methods
Isolation of hAECs
All experiments using hAECs were performed with ap-
proval from the Monash Medical Centre Human Ethics
Committee. Human AECs were isolated as previously de-
scribed [13]. Briefly, placentae were obtained from women
with uncomplicated pregnancies undergoing elective cesarean
section at term. Women gave written, informed consent
for the collection of their placenta. The amnion was
manually stripped from the chorion, and the hAECs
were enzymatically removed by two 1-h digestions using
TrypZean (Sigma-Aldrich, St Lois, MO, USA). Following
digestion, TrypZean was inactivated with Soybean trypsin
inhibitor (Sigma-Aldrich) and the hAECs were collected
by centrifugation (1800 g, 10 mins, RT). Live cell counts
and viability were determined microscopically using try-
pan blue dye exclusion. Cells were cryopreserved using
standard methods at 5 × 106 cells/ml. To thaw, hAEC
sample tubes were quickly removed from liquid nitrogen
and placed directly into a 37 °C water bath until thawed.
Samples were washed with ice cold media to remove
DMSO, and cell counts and viability were determined.
Cells were then transplanted in experimental mice or
analyzed in in vitro assays.
Flow cytometry
Phenotypic analysis by flow cytometry was performed by
staining 0.5–3 × 106 cells with primary antibodies for
20 min at 4 °C. Where appropriate cells were fixed and
permeabilized for intracellular antibody staining accord-
ing to the manufacturer’s instructions. All primary anti-
bodies were purchased from BD Bioscience (San Jose,
CA, USA). The relevant isotype control antibodies were
used as negative controls. Cells were then washed with
fluorescence-activated cell sorting (FACS) buffer [D-PBS
containing 1 % FBS, 5 mM EDTA, 0.02 % (w/v) sodium
azide (Sigma Aldrich)] by centrifugation at 300 g for
5 min at 4 °C. Data acquisition was performed using a
FACSCalibur or FACSCanto II flow cytometer, and data
were analyzed using Flowlogic Software (Inivai Technolo-
gies, Mentone, VIC, Australia).
EAE induction and cell transplantation
All animal experiments were performed with approval
from the Monash University School of Biomedical Sciences
Animal Ethics Committee. EAE was induced in 10–12-
week-old female NOD/Lt mice by subcutaneous injection
of 75 μg extracellular domain of mouse recombinant mye-
lin oligodendrocyte glycoprotein (rMOG; amino acid resi-
dues 1–117 of the mature protein) as previously described
[28]. The mice also received 350 ng pertussis toxin (List
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the time of immunisation and 48 h later. For hAEC trans-
plantation, cells were injected into the peritoneal cavity in
a volume of 200 μl on the days indicated. Control mice re-
ceived injections of equal volumes of phosphate buffered
saline (PBS). The mice were monitored daily, and clinical
scores were assigned according to an arbitrary scale as fol-
lows: 0 normal, 1 loss of tail tone only, 2 weakness in one
or two hind limbs and abnormal gait, 3 hind limb paralysis,
4 hind limb paralysis and fore limb weakness, and 5 dead.
The mice were humanely killed by carbon dioxide asphyxi-
ation upon reaching a score of 4 or at the completion of
the experiment.
T cell proliferation assay and cytokine analysis
Proliferation assays using spleens from MOG TCR trans-
genic (2D2) mice and EAE mice were performed as pre-
viously described [29]. For experiments assessing the
inhibition of T cell proliferation by hAECs, 50 μl of
complete Roswell Park Memorial Institute (RPMI) medium
or 50 μl of hAECs at hAEC to splenocyte ratios ranging
from 1:5 to 1:625 were added to each well prior to the
addition of splenocytes. Cells were incubated at 37 °C for
48 h and then 1 μCi/well [3H]-thymidine (Perkin Elmer,
Waltham, MA, USA) was added for an additional 18 h
of culture. Cells were harvested onto filter mats (Perkin
Elmer) and incorporated radioactive nucleic acids counted
using a Top Count Harvester (Packard Biosciences,
Meriden, CT, USA).
Cytokine analysis was performed as previously described
[29]. For experiments involving inhibition of cytokine pro-
duction by hAECs, 500 μl of complete RPMI medium or
500 μl of hAECs at a hAEC to splenocyte ratio of 1:5 were
added to each well prior to the addition of splenocytes.
Culture supernatant was collected after 72 h, and quanti-
tative analysis of cytokines was performed using a mouse
Th1/Th2/Th17 cytometric bead array (CBA) kit (BD
Bioscience) according to the manufacturer’s instructions.
Data was acquired using a FACSCanto II flow cytometer
(BD Bioscience) and analyzed using FCAP array software
(Soft Flow Inc, Burnsville, MN, USA). The following cyto-
kines were measured: IL-2, IL-4, IL-10, IL-17A, interferon
gamma (IFN-γ), and tumor necrosis factor-alpha (TNF-α).
Mixed lymphocyte reactions
Mononuclear cells from lymphoid tissues were prepared
as above, and mixed lymphocyte reactions were performed.
In brief, cells were seeded in 96-well, flat-bottom microtiter
plates in triplicate. Splenocytes (2 × 105) from C57BL/6
mice (effectors) were incubated with equal numbers of
irradiated (20 Gy) Balb/c stimulators or hAECs. In ex-
periments involving inhibition of allogeneic proliferation,
hAECs were added as third-party cells at a hAEC to sple-
nocyte ratio of 1:5 prior to the addition of splenocytes.Cells were incubated at 37 °C for 4 days and then 1 μCi/
well [3H]-thymidine (Perkin Elmer) was added for an
additional 18 h of culture. Cells were harvested onto filter
mats (Perkin Elmer) and incorporated radioactive nu-
cleic acids counted using a Top Count Harvester (Packard
Biosciences).
T cell phenotyping
Mononuclear cells from lymphoid tissue and the CNS
were prepared as described previously [30], and all cell
counts were performed using a Z2 Coulter cell and par-
ticle counter (Beckman Coulter, Miami, FL, USA). For naïve
T cell staining, cells were stained with appropriately diluted
cell surface antibodies purchased from BD Bioscience.
Analysis of the regulatory T cells (Treg) was performed
with 3 × 106 cells using a FoxP3 staining set (eBioscience)
according to the manufacturer’s instructions. For T helper
cell phenotyping, cells were resuspended at 5 × 106 cells/ml
in complete RPMI medium containing 50 ng/ml PMA
and 1 μg/ml ionomycin. Four microliters Golgistop (BD
Bioscience) was also added for every 6 ml cell culture
medium. Cells were seeded in 24-well plates at 5 × 106
cells per well and incubated for 5 h at 37 °C with 5 %
CO2. Cells were then harvested and counted, and intra-
cellular cytokine staining was performed with 3 × 106
cells using a mouse Th1/Th2/Th17 phenotyping kit (BD
Bioscience), as per the manufacturer’s instructions. Cells
were then analyzed using a FACSCanto II flow cytometer.
Histological assessment of CNS tissue
For histological analysis of CNS tissues, the brain and
spinal cord were dissected from the mice and fixed in
10 % formalin. Paraffin-embedded sections (5 μm) were
cut and stained with hematoxylin-eosin (H&E), luxol fast
blue (LFB), and Bielschowsky silver impregnation to
assess inflammation, demyelination, and axonal damage, re-
spectively, as previously described [29]. Microglia were
identified using rabbit anti-ionized calcium-binding adaptor
molecule 1 (IBA-1) antibody (Wako Pure Chemical Indus-
tries Ltd., Osaka, Japan), raised against synthetic peptide
corresponding to the C-terminal of IBA-1. The antibody
was diluted 1:500 in a PBS solution (0.1 mol/l, pH 7.4). All
sections were treated with a secondary antibody (1:200;
biotinylated anti-rabbit IgG antibody; Vector Laboratories,
Burlingame, CA, USA), and staining was revealed using
3,3′-diaminobenzidine (Pierce Biotechnology, Rockford,
IL, USA). The sections were viewed at a magnification of
either × 100 or × 400 using light microscopy (Olympus
BX-41, Japan). Immunoreactive cells were counted in
three fields of view within a given region on two slides
per animal to give six fields of view per region per animal.
Activated and resting macrophages were identified by
morphology as previously described [20]. Positive and
negative control sections were included in each run.
Table 1 Surface marker expression of hAECs, as determined by
flow cytometry
Surface marker Donor 1 Donor 2 Donor 3
Immunological markers
HLA-ABC ++ ++ ++
HLA-DR − − −
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Results are expressed as the mean ± standard error of
the mean (SEM). Statistical analysis was performed using
Prism 5.03 (GraphPad Software). Experimental and con-
trol groups were compared using one-way ANOVA, and,
where appropriate, Bonferroni post hoc analysis was used.
A value of P < 0.05 was considered statistically significant.CD80 − − −
CD86 − − −
HLA-G ++ ++ +
Phenotypic markers
EpCAM ++ ++ ++
CD90 + + +
CD73 − − −
CD105 − − −
CD45 − − −
CD34 − − −
Integrins
Integrin-α2/CD49b ++ + ++
Integrin-α4/CD49d − − −
Integrin-α6/CD49f ++ + +
Integrin-β1/CD29 ++ ++ ++
Ig superfamily CAMs
ICAM-1/ CD54 − − −
VCAM-1/ CD106 − − −
Other
CXCR4/ CD184 − − −
CD44 − − −
−, Not detected; +, low-intermediate expression (5–50 %); ++, high expression
(>50 %)Results
Phenotypic characteristics of hAEC
hAECs utilized in this study were obtained from a pri-
mary tissue source, not a cell line, and consequently do
not have a defined immunological profile. Due to the
importance of major histocompatibility complex (MHC)
classes I and II molecules in controlling immune responses,
the expression of immunological markers on freshly
isolated hAECs from three separate amnion donors was
examined. The immunological markers analyzed included
HLA-ABC (MHC class I), HLA-DR (MHC class II), co-
stimulatory markers CD80 and CD86, and the immune
regulatory antigen, HLA-G [12, 31]. All hAECs, regardless
of donor, did not express HLA-DR and co-stimulatory
markers CD80 and CD86 (Table 1). In contrast, all hAECs
were positive for HLA-ABC expression and expressed
intermediate to high levels of HLA-G, consistent with a
previous report [32].
Unlike mesenchymal stromal cells (MSCs), which are
assessed using specific selection criteria [33], there are
no current criteria for hAEC selection. However, if they
are epithelial cells, then they must express epithelial cell
adhesion molecule (EpCAM) and, conversely, be nega-
tive for the MSC markers CD90 and CD105 [13]. There-
fore, further phenotypic characterisation analyzing the
epithelial, mesenchymal, and hematopoietic composition
of isolated hAECs was performed on all three amnion
donor cells (Table 1). All cells were found to be positive
for EpCAM and negative for mesenchymal (CD105, CD73)
and hematopoietic markers (CD45 and CD34), as ex-
pected. Surprisingly, we found all donors expressed CD90,
a MSC marker. While some investigators have also re-
ported this [34], others have only reported CD90 expres-
sion in passaged and not primary cells [35].
In order to determine any other donor-specific differ-
ences that may influence the therapeutic potential of
hAECs, extensive phenotypic profiling of adhesion mol-
ecules and integrins was assessed by flow cytometry
(Table 1). Cells from all three donors were negative for
the hyaluronic acid receptor CD44 and the immunoglobu-
lin superfamily cell adhesion molecules (CAMs), including
the intercellular adhesion molecule-1 (ICAM-1, CD54)
and vascular cell adhesion molecule-1 (VCAM-1, CD106).
The expression of integrins was similar between all hAEC
donors, and all were negative for integrin-α4.Immunosuppressive properties of hAECs in vitro
In view of the important role that T cells play in EAE
pathogenesis [36], the ability of hAECs to suppress T cell
proliferation and activation was examined.
Effects of hAECs on proliferation and cytokine production of
activated T cells
For assessment of the suppressive ability of hAECs, we
implemented a co-culture assay that incorporated hAECs
together with human peripheral blood mononuclear cells
(PBMCs) or mouse splenocytes stimulated with anti-CD3/
CD28 (Fig. 1a, b, respectively). At high concentrations of
hAECs, 1:5 (P < 0.001) and 1:25 (P < 0.05), human PBMC
proliferation was significantly suppressed compared to
PBMC stimulation alone. The proliferative response of
splenocytes from naïve mice to anti-CD3/CD28 stimu-
lation was significantly reduced at all hAEC concentra-
tions tested (P < 0.001). Next, we assessed the ability of
hAECs to suppress antigen-specific activated splenocytes
from the 2D2 mice. These transgenic mice are genetically
Fig. 1 hAECs inhibit T cell responses and allogeneic and xenogeneic proliferation. Proliferative response of human PBMCs (a) or splenocytes from
naïve C57BL/6 mice (b) stimulated with anti-CD3/CD28 antibodies in the presence or absence of hAECs at different hAECs to splenocyte ratios (n = 6
performed in triplicate, *P < 0.05, ***P < 0.001 compared to T cells). c Proliferative response of 2D2 splenocytes stimulated with 20 μg MOG35-55 in the
presence or absence of hAECs at different ratios (n = 6 performed in triplicate, **P < 0.01, ***P < 0.001 compared to T cells). d Cytokine secretion profile
in supernatant from co-cultures of hAECs and 2D2 splenocytes at 1:5 ratio (n = 5, **P < 0.01 ***P < 0.001 compared to T cells). e Proliferative response
of C57BL/6 splenocytes co-cultured with hAECs (n = 4 performed in triplicate, ***P < 0.0001 compared to B6 + Bc). f Proliferative response of C57BL/6
splenocytes co-cultured with irradiated Balb/c splenocytes in the absence or presence of hAECs at hAEC to C57BL/6 T cell ratio of 1:5 (n = 4 preformed
in triplicate, ***P < 0.0001 compared to B6 + Bc). g Cytokine secretion profile in supernatant from MLR cultures with hAECs. (n = 4, *P < 0.05,**P < 0.01,
***P < 0.001 compared to B6 + Bc)
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MOG35-55, resulting in a highly proliferative MOG-
specific T cell response. hAECs were added at differing
ratios to 2D2 splenocytes, and co-cultures were stimu-
lated with 20 μg/ml MOG35-55. As shown in Fig. 1c,
hAECs significantly suppressed the proliferation of MOG-specific T cells at hAEC to splenocyte ratios of 1:5
(P < 0.0001) and 1:25 (P < 0.01) by approximately 75 and
35 %, respectively, as compared to T cells alone. No sig-
nificant differences were observed at 1:125 and 1:625.
These data indicate that hAECs were able to suppress
the proliferation of autoantigen-specific T cells in a dose-
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MOG35-55 stimulated 2D2 splenocytes co-cultured with
hAECs at a ratio of 1:5, and cytokines were quantified by
CBA. A significant reduction in the pro-inflammatory
cytokines IFN-γ (P < 0.01) and TNF-α (P < 0.001) as
well as the anti-inflammatory cytokine IL-10 (P < 0.01)
was observed in the presence of hAECs (Fig. 1d), while no
change in IL-2, IL-17A, or IL-4 was detected (Fig. 1d).Effect of hAECs on allogeneic T cell proliferation and
cytokine production
We next analyzed the in vitro suppressive effects of
hAECs in a one-way MLR. Co-cultures were established
using C57BL/6 responder splenocytes and irradiated
Balb/c stimulator splenocytes, with hAECs added as
third-party cells at a ratio of 1:5. In contrast to the
highly proliferative allogeneic reaction induced by Balb/c
stimulators (P < 0.001), human-derived AECs did not
stimulate a xenogeneic T cell response when cultured
with C57BL/6 responders (Fig. 1e) and no difference in
T cell proliferation was observed in the presence of
hAECs when compared to C57BL/6 cells alone. Notably,
hAECs were able to significantly suppress allogeneicFig. 2 hAECs inhibit upregulation of T cell activation markers and retain T
anti-CD3/CD28 in the presence or absence of hAECs for 5 days and then ana
on stimulated CD4+ T cells. c, d Representative profiles of CD44 and CD62L e
naïve T cells, CD62LloCD44hi denotes memory cells. Data are representative oimmune responses between splenocytes from C57BL/6
and Balb/c mice (P < 0.001; Fig. 1f ), the proliferation be-
ing reduced by 80 %. We next examined how hAECs
exerted their suppressive effect on T cells by analyzing
cytokine production in culture supernatants. As shown
in Fig. 1g, the addition of hAECs at 1:5 significantly re-
duced the production of IL-2 (P < 0.001), IFN-γ (P < 0.01
and P < 0.05, respectively), TNF-α (P < 0.001), and IL-10
(P < 0.01). No changes were observed for IL-17A or IL-4.Inhibition of activation and maintenance of a naïve
phenotype of T cells co-cultured with hAECs
We next assessed the direct effect of hAEC co-culture
on the expression of the activation marker CD25 on T
cells. For this, naïve CD4+ T cells (CD62LhiCD44lo) were
isolated from the spleens of the C57BL/6 mice and stimu-
lated with anti-CD3/anti-CD28 in the presence or absence
of hAECs (Fig. 2). After 5 days of culture, T cells were col-
lected and examined for the expression of CD25, CD62L,
and CD44 using flow cytometry. Stimulation of naïve T
cells alone resulted in the upregulation of CD25 (Fig. 2a),
with 42.3 % of CD4+ T cells exhibiting a memory pheno-
type (CD62LloCD44hi) and 31.3 % remaining in a naïvecells in a naïve phenotype. Naïve CD4+ T cells were stimulated with
lyzed by flow cytometry. a, b Representative profiles of CD25 expression
xpression on stimulated CD4 + CD25+ T cells. CD62LhiCD44lo denotes
f two independent experiments with n = 3 mice
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was a large reduction in the upregulation of CD25 (Fig. 2b)
and significantly less CD4+ T cells acquired a memory
phenotype. Indeed, only 12.8 % of T cells expressed a
memory phenotype and 60.3 % retained their naïve pheno-
type (Fig. 2d).
Administration of hAECs ameliorates relapsing-remitting
EAE in a dose-dependant manner
In vitro data indicated that hAECs are potent suppressors
of immune cell activation and proliferation. To test whether
hAECs could provide a therapeutic benefit in an inflamma-
tory setting, we used a relapsing-remitting EAE mouse
model. Following EAE induction, we injected either one or
five million hAECs at the onset of disease on days 8, 10,
and 12. A significant amelioration of EAE severity was seenFig. 3 Administration of hAECs on day 8, 10, and 12 suppresses the develo
one or five million hAECs or PBS on day 8, 10, and 12 (indicated by arrows
disease score (c) of NOD/Lt mice injected i.p. with 0.1, 0.25, or 0.5 million h
compared to PBS). Representative spinal cord sections from PBS control mi
that received five million hAECs stained with H&E (e), LFB (g), or Bielschow
damage, respectively. Magnification × 100. IBA-1+ immunoreactivity in the
received five million hAECs (k). Magnification × 400. (l) Total number of IBA
hAEC-treated mice (*P < 0.05 compared to PBS)in the daily clinical scores following the administration of
both doses of hAECs (P < 0.05; Fig. 3a), as compared to the
PBS group. Importantly, the PBS control mice relapsed at
day 24, while hAEC-treated mice did not relapse for the
duration of the study, suggesting that cell administration
also prevented relapse in these mice. The incidence of
disease in the PBS control group was 100 %, while hAEC
administration decreased the incidence to 57 and 42 % for
the groups receiving one or five million cells, respectively
(Table 2). There was no significant difference in the day of
onset of clinical signs between the groups. However, the
maximum disease scores and cumulative disease scores
were significantly (P < 0.05) reduced in both the hAEC cell
treatment groups compared to the PBS group.
Neuropathological evaluation of CNS tissues from the
PBS group showed extensive inflammatory lesions, whichpment of RR-EAE. a Clinical scores of NOD/Lt mice injected i.p. with
) (n = 7, *P < 0.05 compared to PBS). Clinical scores (b) and cumulative
AECs or PBS on day 1 and 3 (indicated by arrows) (n = 6–7, **P < 0.01
ce stained with H&E (d), LFB (f), or Bielschowsky silver stain (h) or mice
sky silver stain (i) to assess inflammation, demyelination, and axonal
grey matter of spinal cord sections from PBS controls (j) or mice that
-1+ cells/mm2 in different regions of the CNS in PBS controls and
Table 2 Clinical outcome of relapsing-remitting-EAE mice treated
with hAECs
1 × 106 hAECs 5 × 106 hAECs PBS
Disease incidence 4/7 3/7 7/7
Day disease onset 17.25 ± 5.3 15.7 ± 2.0 16.7 ± 1.6
Death severe disease 1/7 1/7 3/7
Maximum score 1.9 ± 0.6* 1.3 ± 0.7* 3.8 ± 0.5
Cumulative score 24.9 ± 10.2* 20.8 ± 12.0* 57.3 ± 9.79
*P < 0.05 compared to PBS
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matory cells in H&E stained sections (Fig. 3d). Luxal fast
blue (Fig. 3f) and Bielschowsky silver staining (Fig. 3h)
also showed marked myelin loss and severe axonal injury,
respectively, particularly around lesioned tissue within the
dorsal column of the spinal cord. Analysis of histological
sections from the mice transplanted with five million cells
revealed little cellular infiltration with minimal demyelin-
ation and axonal damage (Fig. 4e, g, i). Furthermore, we
assessed IBA-1+ immunoreactivity, which stains microglia
and macrophages, within different regions of the CNS. A
significant decrease in IBA1+ cells was found in both the
white and gray matters of the spinal cord, following hAEC
administration compared to the PBS controls (Fig. 3j, k,
respectively). No difference was observed in the cortex,
periventricular, or subcortical white matter (Fig. 3l). Col-
lectively, administration of hAECs into RR-EAE results in
amelioration of both clinical and neuropathological signs
of disease.
As hAEC administration was effective in ameliorating
RR-EAE, we titrated the number of cells administered to
determine whether suppression of EAE by hAECs was
dose-dependant. To that effect, hAECs were administered
i.p. at three different concentrations, 0.5, 0.25, and 0.1 million.
A dose-dependant attenuation of EAE severity was observedFig. 4 T cell responses in RR-EAE mice following hAEC administration. Mon
37. Proliferative response of splenocytes stimulated with rMOG (a) or anti-C
stimulated splenocyte cultures. h–l Cytokine secretion profile in supernatan
in triplicate, *P < 0.05 compared to PBS)with an increasing cell dose (Fig. 3b). The two highest doses
of hAECs significantly reduced the cumulative disease score
(P < 0.01), a trend that was almost significant following
administration of only 0.1 million hAECs (P = 0.058;
Fig. 3c). Administration of 0.5 million hAECs signifi-
cantly reduced the maximum disease score compared
to the PBS control group (P < 0.05; Table 3). No signifi-
cant differences were observed between the groups in
terms of the disease incidence, day of disease onset, or
death due to severe disease (Table 3).
Effect of hAEC administration on peripheral immune
responses in RR-EAE
Having shown that hAEC administration ameliorates
RR-EAE disease severity in a dose-dependant manner,
the effect on peripheral immune responses was then ex-
amined. Splenocytes from the treated mice were isolated
and stimulated in vitro with either rMOG or anti-CD3/
CD28 for 72 h. In comparison to the PBS control group,
a trend towards decreased MOG-specific proliferation
was seen in the hAEC-treated groups receiving either
one or five million hAECs (Fig. 4a). This was accompan-
ied by a significant decrease in IL-17A (P < 0.05; Fig. 4b)
and TNF-α secreted in splenocyte cultures from the
mice that received hAECs (Fig. 4d). In contrast, a signifi-
cant increase in the secretion of the anti-inflammatory
cytokine IL-4 was observed in the mice that received
hAECs (P < 0.05; Fig. 4e). No difference in MOG-specific
secretion of IFN-γ (Fig. 4c) or IL-10 (Fig. 4f) was observed
between the groups. It is noteworthy that this cytokine
profile of decreased IL-17A and increased IL-4 observed
following hAEC administration was also found to be dose-
dependant (data not shown).
The effect of hAEC administration on non-specific per-
ipheral immune responses was also determined by stimu-
lating splenocytes with anti-CD3/CD28. No reduction inonuclear cells were isolated from the spleen of NOD/Lt mice at day
D3/CD28 (g). b–f Cytokine secretion profile in supernatant from rMOG
t from anti-CD3/CD28 stimulated splenocyte cultures (n = 6 performed
Table 3 Clinical results from hAEC dose titration
hAEC 0.1 hAEC 0.25 hAEC 0.5 PBS
Disease incidence 5/6 5/6 5/6 7/7
Day disease onset 12.8 ± 0.6 17.0 ± 3.7 14.0 ± 1.3 12.0 ± 0.4
Death severe disease 1/6 2/6 0/6 2/7
Maximum score 2.3 ± 0.7 3.1 ± 0.8 1.8 ± 0.5* 3.6 ± 0.4
Cumulative score 37.6 ± 11.3 24.3 ± 7.8** 17.8 ± 7.5** 71.2 ± 11.1
*P < 0.05, **P < 0.01, compared to PBS
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of cytokines such as IL-17A (Fig. 4h), IFN-γ (Fig. 4i), and
TNF-α (Fig. 4j) was observed following the transplantation
of hAECs. Importantly, a significant increase in IL-4 se-
cretion was observed in both the hAEC-treated groups
compared to PBS (P < 0.05; Fig. 4k). Collectively, these
data suggest that T cells had acquired a Th2-biased pheno-
type in the mice that received hAECs.
hAEC administration increases the number of T
regulatory cells and naïve CD4+ T cells in the periphery
To gain a better understanding of the mechanism by which
protection against EAE was afforded by hAECs, the propor-
tions and total numbers of CD4 +CD25 + FoxP3+ Tregs
were examined in the lymph nodes and spleen. A trend to-
wards decreased total cell numbers was observed in the
lymph nodes (Fig. 5a) and spleen (Fig. 5d) of the PBS con-
trol mice compared to both the hAEC-treated groups. No
change in the proportion of Tregs was detected between
the groups in the lymph nodes (Fig. 5b); however, a trend
towards increased total Treg numbers was observed in the
lymph nodes of both the hAEC-treated groups (Fig. 5c).
Similarly, no change in the proportion of Tregs was ob-
served in the spleen (Fig. 5e); however, a significant increase
in total Treg numbers was observed in the spleen of the
mice that received five million hAECs compared to the PBS
controls (P < 0.05; Fig. 5f). Moreover, when the presence of
naïve CD4+ T cells in the spleen was investigated, no
change in proportion could be found between the groups
(Fig. 5g). However, a significant increase in the total num-
ber of naïve CD4+ T cells was observed in the mice that re-
ceived one million hAECs compared to the PBS controls
(P < 0.05; Fig. 5h). Based on these results, the protection
afforded by hAECs in the EAE mice appeared to be medi-
ated, in part, by an increase in the number of Tregs and
naïve CD4+ T cells in peripheral lymphoid organs.
Effect of hAEC administration on CD4+ T helper cell
subsets
Using IFN-γ, IL-4, and IL-17A as biomarkers of Th1,
Th2, and Th17 cells, respectively, we examined the
percentage of these CD4+ T helper cells in the periphery
and CNS of the hAEC-treated mice. Within the spleen,
there was a significant increase in the proportion ofCD4 + IFN-γ + T cells (P < 0.05; Fig. 6a) compared to the
PBS controls and a trend towards increased proportions
of CD4 + IL17-A+ T cells (Fig. 6b). The proportion of
CD4 + IL-4+ Th2 cells was found to be significantly
increased in the spleens of the mice receiving hAECs at
doses of one million (P < 0.05) and 5 million (P < 0.01)
cells, compared to the PBS control group (Fig. 6c). The
increase in Th1 and Th17 cells was not observed in the
lymph nodes (Fig. 6f, g, respectively), although a Th2 shift,
indicated by a significant increase in the proportion
of CD4 + IL-4+ cells, was observed in the group of mice
receiving one million AECs (P < 0.05; Fig. 6h). Finally, in
the CNS, no differences were observed in the proportions
of CD4 + IFN-γ + and CD4 + IL-17+ T cells between the
groups (Fig. 6k, l, respectively). However, there were in-
creases in the proportion of CD4 + IL-4+ T cells in the
mice that received hAECs, with figures reaching signifi-
cance in the mice transplanted with five million hAECs
(P < 0.05; Fig. 6m), compared to the PBS control group.
Recent evidence has suggested that both Th1 and Th17
cells play a role in EAE pathogenesis. We therefore de-
termined the ratio of Th1 to Th2 and Th17 to Th2 cells
within the spleen, lymph nodes, and CNS. Within the
spleen, the Th1 to Th2 (P < 0.01; Fig. 6d) and Th17 to
Th2 (P < 0.05; Fig. 6e) ratios were significantly decreased
in the mice that received five million hAECs compared to
PBS, suggesting a shift towards an anti-inflammatory Th2
phenotype. This finding is in line with our previous results
that found increased secretion of IL-4 in spleen cultures
(Fig. 4e, k). Analysis of the Th1 to Th2 ratio in the lymph
nodes trended towards a reduction in the Th1 to Th2 ratio
in both the hAEC-treated groups compared to the PBS
control (Fig. 6i), and the Th17 to Th2 ratio in the lymph
nodes was significantly reduced following hAEC adminis-
tration (P < 0.01; Fig. 6j). Upon examination of the Th1 to
Th2 (Fig. 6n) and Th17 to Th2 (Fig. 6o) ratios in the CNS,
a highly significant decrease in both ratios was observed
between the group receiving five million hAECs and the
PBS control group (P < 0.001 and P < 0.01, respectively).
Collectively, these data indicate an equilibration of the
Th1 to Th2 and Th17 to Th2 balance and a bias towards a
Th2 phenotype within the peripheral immune organs and
the CNS following hAEC transplantation.
Discussion
hAECs are a novel source of stem cells that can be
obtained in large quantities [13] and possess potent im-
munosuppressive properties [5, 15]. In the current study,
we examined whether the administration of hAECs in a
RR-EAE model could modulate the immune response
and suppress MOG-induced EAE development. Our
results show that transplantation of hAECs at the time
of disease onset significantly ameliorates RR-EAE by inhi-
biting pathogenic T cell responses, namely Th17 and Th1
Fig. 5 Administration of hAECs increases the total number of Tregs and naïve CD4+ T cells in the periphery. Mononuclear cells were isolated from the
lymph nodes and spleen at day 37, and the proportion and number of Tregs or naïve CD4+ T cells was analyzed by flow cytometry. a Total cell number
in the lymph nodes. b Proportion of gated lymphocytes that are CD4 + CD25 + Foxp3+ Tregs in the lymph nodes. c Total Treg numbers in the lymph
nodes. d Total cell number in the spleen. e Proportion of gated lymphocytes that are CD4 + CD25 + Foxp3+ Tregs in the spleen. f Total Treg numbers in
the spleen. g Proportion of CD4+ that are naïve (CD62LhiCD44lo) T cells in the spleen. h Total number of CD4+ naïve (CD62LhiCD44lo) T cells in the
spleen. (n= 6, *P< 0.05 compared to PBS)
McDonald et al. Journal of Neuroinflammation  (2015) 12:112 Page 10 of 14cells within the periphery and CNS. We propose that
this effect is mediated by an increase in the number of
peripheral T regulatory cells, an increase in the pool of
naïve CD4+ T cells, and a shift towards a Th2 dominant
environment.
Given that hAECs are routinely isolated from different
donors, it is important for their future clinical application
that donor-specific variations are assessed. We confirmed
that hAECs do not express HLA class II antigen (HLA-DR)
or co-stimulatory factors CD80 and CD86 [12], and no
variation between donors was noted. However, we did
observe expression of HLA class I antigens in cells from
all of our donors, which is in contrast to previous reports
[9, 37] and may lead to an increased risk of transplantrejection. The expression of HLA-G, a non-classical class
I antigen, is most commonly expressed on placental tissues
[38, 39], including amnion [32]. We found that there was
variation in HLA-G expression between donors. While all
were positive, some had threefold higher expression than
others. It has previously been reported that preterm am-
nion expresses less HLA-G than term amnion [32]. It is
possible that HLA-G expression is related to proximity to
the timing of birth. Furthermore, upon analysis of CD90,
we found discrepancies to previous literature that have
stated that hAECs are negative for this marker [13]. In this
current study, we did not directly compare the in vivo effi-
cacy between the different donors, but given the differ-
ences in HLA-G and CD90 expression, these future studies
Fig. 6 Administration of hAECs increases Th2 cells in the CNS and shifts the inflammatory profile towards an anti-inflammatory environment.
Mononuclear cells were isolated from NOD/Lt mice at day 37 and the phenotype of T helper cells was assessed by flow cytometry. Th1 (CD4 + IFN-γ+),
Th17 (CD4 + IL-17+), and Th2 (CD4 + IL-4+) cell proportions and the Th1 to Th2 and Th17 to Th2 ratios were determined in the spleen (a–e), lymph
nodes (f–j), and CNS (k–o) (n = 6, *P < 0.05, **P < 0.01, ***P < 0.001)
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between the donors in this study suggest that the pre-
screening of amnion donors may be required in order
to identify those most suitable for use in specific clin-
ical applications, such as the treatment of MS patients.
As shown here, hAECs posses potent immunomodula-
tory properties capable of suppressing antigen-specific,
non-specific, and allogeneic T cell responses in vitro,
including human PBMC proliferation. While it has pre-
viously been shown that hAECs do not stimulate allo-
geneic proliferation when cultured with PBMCs [12],
our observations further demonstrate that these cells do
not elicit a xenogeneic response from mouse splenocytes.
The immune suppressive activity of hAECs in vitro was
associated with a significant decrease in Th1 cytokines, in-
cluding IFN-γ and TNF-α. It is interesting to note that
hAECs did not influence secretion of IL-17A and IL-4 in
in vitro assays, while in vivo, hAEC treatment led to de-
creased IL-17A and increased IL-4 secretion. This may be
explained by differences in mouse strain (C57BL/6 versus
NOD/Lt) and stimulating antigen (MOG35-55 versus re-
combinant MOG protein) used in the in vitro and in vivoexperiments. While these results are not directly compar-
able, it is noteworthy that hAECs suppress proliferation
and pro-inflammatory cytokines in both settings, thus
demonstrating their broad immunosuppressive properties.
In examining the in vitro suppressive effect of hAECs, we
show here for the first time that hAECs restrain naïve
CD4+ T cells from developing into an activated pheno-
type. This was demonstrated by inhibition of the upregu-
lation of two markers, the T cell activation marker CD25,
and the adhesion receptor CD44. This is important in the
context of MS pathogenesis, since MS patients have more
myelin-reactive effector/memory T cells compared to
healthy controls [40]. In the EAE mice, CD44 has been
shown to be involved in both the differentiation of Th1/
Th17 cells [41] and the extravasation of effector/memory
CD62LloCD44hi T cells into the CNS [42, 43].
The ability of a single dose of two million hAECs to
ameliorate EAE has previously been shown in the C57BL/
6 mice [18], and our earlier work has also demonstrated
that a single dose of one million hAECs can suppress EAE
in the NOD/Lt mice [17]. Results presented here extend
these findings by demonstrating that low-dose (1 × 106)
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were effective in significantly ameliorating clinical and
pathological signs of RR-EAE in the NOD/Lt mice. We
also demonstrate for the first time that hAECs ameliorate
EAE in a dose-dependant manner and importantly, as
little as 100,000 hAECs suppressed clinical signs of the
disease. We have previously investigated the efficacy of
different sources of MSCs [29] and neural stem cells
(NSCs) [28] in EAE and have never observed significant
amelioration of disease when less than one million cells
were transplanted. While not directly comparable, the
current results suggest that hAECs are more powerful
in suppressing EAE than MSCs and NSCs.
Liu et al. [18] have previously suggested that hAECs
work via a Th2 shift based on the single observation that
IL-5 was increased in the EAE mice treated with hAECs.
However, no change in other cytokines, including IL-4,
IL-17, IFN-γ, TNF-α, or IL-10, was reported. Moreover,
no investigation was performed on the individual T
helper cell phenotypes. In that study, EAE was induced
in the C57BL/6 mice resulting in chronic progressive
paralysis, a model that displays different immune responses
compared to the relapsing-remitting EAE in the NOD/Lt
mice [44]. Furthermore, Liu et al. [18] transplanted cells
intravenously, whereas we delivered cells into the intraperi-
toneal cavity. While we cannot exclude the possibility that
the variability seen in the cytokine secretion between these
two studies is due to the strain of mice used for EAE, as
well as the route of hAECs injection, it is noteworthy that
we have previously shown that both administration routes
are effective for reducing clinical signs [29]. In our study,
we unequivocally show that, together with the decrease
in clinical scores, we observed a significant decrease in
MOG-specific secretion of IL-17A and a significant in-
crease in IL-4, a Th2 cytokine that has been associated
with spontaneous EAE recovery [45] and reduction in
disease severity [46]. Importantly, the decreased secre-
tion of IL-17A was observed in spite of the significant
increase in the proportion of Th17 and Th1 cells within
the spleen. Collectively, these data suggest that the in-
creased proportion of Th1 and Th17 cells in the spleens
of the hAEC-treated mice produce less pro-inflammatory
mediators and are under the tight regulatory control of ei-
ther Th2 or other regulatory cell types. This was verified
by examining the Th1 to Th2 and Th17 to Th2 ratios,
whereby the mice receiving five million hAECs displayed a
significant Th2 shift.
Regulatory T cells play a key role in controlling im-
mune responses and protect against the development of
EAE [47]. In our study, increased numbers of Treg cells
were observed in the peripheral lymphoid tissues of the
mice that received hAECs. Using a model of fibrotic
lung injury, we have recently shown that hAECs induce
Treg polarisation and these Tregs were critical formacrophage polarisation and subsequent injury reso-
lution [48]. Taken together, it is clear that hAECs have
the ability to influence Tregs and this functional property
is critical to their overall therapeutic efficacy. Studies using
other placental-derived cells have found similar effects
with increased Treg polarisation and downregulation of
Th1 and Th17 responses in normal PBMCs and collagen
reactive T cells from arthritis patients [49, 50]. Given the
plasticity of CD4 cell subsets, further studies are required
to define how hAECs regulate the differentiation of T
helper cells and Tregs. We showed in vitro that hAECs
had the ability to restrain naïve CD4+ T cells from acquir-
ing a memory phenotype upon activation. Therefore, in
our in vivo studies, we examined the naïve CD4+ T cell
pool and similarly found a significant increase in the num-
ber of naïve CD4+ T cells in the mice treated with the low
dose of one million hAECs compared to the PBS controls.
This demonstrates that hAECs also have the ability to sup-
press the activation of T cells in vivo, which has not been
shown previously.
While our findings show that hAECs act via modula-
tion of peripheral immune responses, administration of
hAECs also modulates the immune response directly
within the CNS. This was demonstrated by a decrease in
microglia and macrophages within both the gray and
white matters of the CNS. Not only were there less over-
all numbers of macrophages and microglia, but the acti-
vation state of microglia was decreased, with more
resting microglia present following hAEC administration
(data not shown). Furthermore, an increase in the pro-
portion of CD4 + IL-4+ T cells directly within the CNS
was also observed in the mice that received hAECs. In-
creased IL-4 levels within the CNS of the EAE mice
have been associated with decreased demyelination
and axonal pathology [51] as well as promoting the re-
cruitment of Tregs [52]. Th2 cytokines have also been
found to have a positive effect on neuronal cultures by
upregulating arginase, which can aid in neuroprotection
by decreasing NO generation and enhancing neurite out-
growth [53]. The mechanism behind the increase in Th2
cells observed in the periphery and within the CNS fol-
lowing hAEC administration has not yet been elucidated.
It has been shown that MSCs derived from adipose have
the ability to upregulate chemokine receptor expression,
such as CCR4, on peripheral lymphocytes [54]. It may be
that hAECs are programming Th2 cells in the peripheral
lymphoid organs to increase their expression of CCR4,
which has been implicated in increased Th2 trafficking to
the CNS during disease [55].
Although we did not use a control cell type in the current
study, previous work, including our own, has clearly dem-
onstrated that not all mouse and human cell types are cap-
able of significantly attenuating clinical and pathological
disease in EAE mice [28, 29, 56]. Based on this current
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the current setting is due to the immunosuppressive and
reparative properties of hAECs rather than a non-specific
response to cell transplantation. Moreover, even though
our results suggest that hAECs do not elicit a xenogeneic T
cell response in vitro, we cannot rule out the possibility that
the induction of an innate or humoral immune response to
the injected cells may cause their subsequent rejection.
Nevertheless, there is very strong evidence in current litera-
ture that shows long-term engraftment of transplanted cells
is not required for therapeutic benefit [57–59].
Conclusion
hAECs offer a new and promising alternative to other
stem cell types that are easily obtained in the large quan-
tities required for therapeutic transplantation. Our results
demonstrate that hAECs posses potent immunomodula-
tory properties and protect mice from developing signs of
RR-EAE when administered in the peritoneum. hAECs
appear to elicit their immunomodulatory effects in EAE
through promoting Tregs, maintaining the peripheral
naïve CD4+ T cell pool and stimulating an anti-
inflammatory Th2 environment, leading to the suppres-
sion of pathogenic T cell responses in peripheral second-
ary lymphoid organs and within the CNS. These attributes
make hAECs an attractive cellular therapy for neurode-
generative diseases such as MS.
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